These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23493434)

  • 21. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
    Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
    Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
    Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
    J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
    Mallick U; Harmer C; Yap B; Wadsley J; Clarke S; Moss L; Nicol A; Clark PM; Farnell K; McCready R; Smellie J; Franklyn JA; John R; Nutting CM; Newbold K; Lemon C; Gerrard G; Abdel-Hamid A; Hardman J; Macias E; Roques T; Whitaker S; Vijayan R; Alvarez P; Beare S; Forsyth S; Kadalayil L; Hackshaw A
    N Engl J Med; 2012 May; 366(18):1674-85. PubMed ID: 22551128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
    Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
    World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancer.
    Pitoia F; Bueno F; Cross G
    Clin Nucl Med; 2014 Sep; 39(9):784-90. PubMed ID: 24999689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermediate-risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long-term outcome study.
    Ballal S; Soundararajan R; Garg A; Chopra S; Bal C
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):408-16. PubMed ID: 25823589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
    Silberstein EB
    J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
    Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
    Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma.
    Kim EY; Kim TY; Kim WG; Yim JH; Han JM; Ryu JS; Hong SJ; Yoon JH; Gong G; Kim WB; Shong YK
    Nucl Med Commun; 2011 Oct; 32(10):954-9. PubMed ID: 21849927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparable Ablation Efficiency of 30 and 100 mCi of I-131 for Low to Intermediate Risk Thyroid Cancers Using Triple Negative Criteria.
    Fatima N; Zaman MU; Zaman A; Zaman U; Tahseen R
    Asian Pac J Cancer Prev; 2016; 17(3):1115-8. PubMed ID: 27039734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioactive Iodine Therapy in Differentiated Thyroid Cancer: An Update on Dose Recommendations and Risk of Secondary Primary Malignancies.
    Nguyen NC; Anigati EM; Desai NB; Öz OK
    Semin Nucl Med; 2024 Jul; 54(4):488-496. PubMed ID: 38772827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases.
    Sabra MM; Grewal RK; Ghossein RA; Tuttle RM
    Thyroid; 2014 Jul; 24(7):1088-95. PubMed ID: 24559250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of recurrence rates in papillary thyroid microcarcinoma patients with and without histopathological risk factors after radioiodine ablation treatment.
    Soydal C; Araz M; Ozkan E; Arslantaş E; Kucuk ON; Aras G
    Nucl Med Commun; 2015 Feb; 36(2):109-13. PubMed ID: 25321158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
    Stevic I; Dembinski TC; Pathak KA; Leslie WD
    Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Result of Multiple I-131 Treatments on the Effective Half-Life of Retained Radioactivity in Patients Ablated for Differentiated Thyroid Cancer: Possible Evidence for Thyroid Remnant Function Impairment.
    Okkalides D
    Cancer Biother Radiopharm; 2016 Mar; 31(2):58-64. PubMed ID: 26986816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
    Vassilopoulou-Sellin R; Schultz PN; Haynie TP
    Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remnant uptake as a postoperative oncologic quality indicator.
    Schneider DF; Ojomo KA; Chen H; Sippel RS
    Thyroid; 2013 Oct; 23(10):1269-76. PubMed ID: 23373869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
    Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.